Sorokins Vladimirs, Tilgase Andra, Olmane Evija, Isajevs Sergejs, Zablocka Tatjana, Rasa Agnija, Alberts Pēteris
Department of Surgery, Balvi and Gulbene Hospital, Balvi, Latvia.
Rigvir, Riga, Latvia.
SAGE Open Med Case Rep. 2020 Jun 23;8:2050313X20934978. doi: 10.1177/2050313X20934978. eCollection 2020.
Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first oncolytic virus registered in Latvia. A female patient was diagnosed with stage IIIB melanoma in December 2012, over 9.4 years ago. After the first excision and re-excision, the patient had several recurrences and disease progressions. After the patient had received surgical treatment in 2014, ECHO-7 virus oncolytic virotherapy was started. Since then, the patient has experienced only one more disease progression episode in May 2015 and has been stable for over 60 months. The patient has not received any other treatment than surgery and oncolytic virotherapy. No severe adverse events have been reported during virotherapy. The present case suggests that ECHO-7 virotherapy is an effective treatment of skin melanoma.
黑色素瘤是一种侵袭性皮肤癌，预后严重。目前的研究结果表明，溶瘤病毒治疗黑色素瘤具有很高的治疗潜力。ECHO-7（Rigvir）是拉脱维亚注册的第一种溶瘤病毒。一名女性患者于9.4多年前，即2012年12月被诊断为IIIB期黑色素瘤。首次切除和再次切除后，患者出现多次复发和疾病进展。2014年患者接受手术治疗后，开始使用ECHO-7病毒进行溶瘤病毒疗法。从那时起，患者仅在2015年5月经历了一次疾病进展，并且已经稳定了60多个月。除了手术和溶瘤病毒疗法外，患者未接受任何其他治疗。在病毒疗法期间未报告严重不良事件。本病例表明，ECHO-7病毒疗法是治疗皮肤黑色素瘤的有效方法。
